Clinical Trials | December 22, 2025
Ipsen’s FALKON trial falls short in rare FOP study, offers key insights
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
The positive CHMP opinion is supported by results from the Phase III QUASAR trial
At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
Subscribe To Our Newsletter & Stay Updated
